These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39240784)

  • 1. Macrophage Membrane Spontaneously Encapsulated Cyclodextrin-Based Nanomedicines for Improving Lipid Metabolism and Inflammation in Atherosclerosis.
    Mou N; Duan X; Qu K; Chen Q; He Z; Cao Y; Zhang K; Qin X; Zhu L; Han Z; Li C; Zhong Y; Wu W
    ACS Appl Mater Interfaces; 2024 Sep; 16(37):49660-49672. PubMed ID: 39240784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage Membrane-Encapsulated Dopamine-Modified Poly Cyclodextrin Multifunctional Biomimetic Nanoparticles for Atherosclerosis Therapy.
    Zhu L; Zhong Y; Yan M; Ni S; Zhao X; Wu S; Wang G; Zhang K; Chi Q; Qin X; Li C; Huang X; Wu W
    ACS Appl Mater Interfaces; 2024 Jun; 16(25):32027-32044. PubMed ID: 38867426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapy of Atherosclerosis by a Broad-Spectrum Reactive Oxygen Species Scavenging Nanoparticle with Intrinsic Anti-inflammatory Activity.
    Wang Y; Li L; Zhao W; Dou Y; An H; Tao H; Xu X; Jia Y; Lu S; Zhang J; Hu H
    ACS Nano; 2018 Sep; 12(9):8943-8960. PubMed ID: 30114351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Macrophage Membrane-Functionalized, Reactive Oxygen Species-Activatable Nanoprodrug to Alleviate Inflammation and Improve the Lipid Metabolism for Atherosclerosis Management.
    Qu K; Zhong Y; Zhu L; Mou N; Cao Y; Liu J; Wu S; Yan M; Yan F; Li J; Zhang C; Wu G; Zhang K; Qin X; Wu W
    Adv Healthc Mater; 2024 Oct; 13(26):e2401113. PubMed ID: 38686849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques.
    Alaarg A; Zheng KH; van der Valk FM; da Silva AE; Versloot M; van Ufford LC; Schulte DM; Storm G; Metselaar JM; Stroes ES; Hamers AA
    Vascul Pharmacol; 2016 Jul; 82():51-9. PubMed ID: 27189780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis.
    Dou Y; Chen Y; Zhang X; Xu X; Chen Y; Guo J; Zhang D; Wang R; Li X; Zhang J
    Biomaterials; 2017 Oct; 143():93-108. PubMed ID: 28778000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr
    Yu M; Amengual J; Menon A; Kamaly N; Zhou F; Xu X; Saw PE; Lee SJ; Si K; Ortega CA; Choi WI; Lee IH; Bdour Y; Shi J; Mahmoudi M; Jon S; Fisher EA; Farokhzad OC
    Adv Healthc Mater; 2017 Oct; 6(20):. PubMed ID: 28730752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bifunctional supramolecular nanofiber inhibits atherosclerosis by enhancing plaque stability and anti-inflammation in apoE
    Shang Y; Ma C; Zhang J; Wang Z; Ren C; Luo X; Peng R; Liu J; Mao J; Shi Y; Fan G
    Theranostics; 2020; 10(22):10231-10244. PubMed ID: 32929345
    [No Abstract]   [Full Text] [Related]  

  • 9. Resveratrol inhibits lipid accumulation in the intestine of atherosclerotic mice and macrophages.
    Ye G; Chen G; Gao H; Lin Y; Liao X; Zhang H; Liu X; Chi Y; Huang Q; Zhu H; Fan Y; Dong S
    J Cell Mol Med; 2019 Jun; 23(6):4313-4325. PubMed ID: 30957417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. I
    Ma L; Qian L; Ying Q; Zhang Y; Zhou C; Wu G
    Mol Cell Endocrinol; 2017 Jan; 440():80-92. PubMed ID: 27725191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclodextrin-mediated conjugation of macrophage and liposomes for treatment of atherosclerosis.
    Gao C; Liu C; Chen Q; Wang Y; Kwong CHT; Wang Q; Xie B; Lee SMY; Wang R
    J Control Release; 2022 Sep; 349():2-15. PubMed ID: 35779655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted delivery of berberine using bionic nanomaterials for Atherosclerosis therapy.
    Wu H; Zhang L; Dong X; Yang J; Zheng L; Li L; Liu X; Jin M; Zhang P
    Biomed Pharmacother; 2024 Sep; 178():117135. PubMed ID: 39047421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2,3,4',5-tetrahydroxystilbene-2-O-β-d-glycoside attenuates atherosclerosis in apolipoprotein E-deficient mice: role of reverse cholesterol transport.
    Chen X; Tang K; Peng Y; Xu X
    Can J Physiol Pharmacol; 2018 Jan; 96(1):8-17. PubMed ID: 28863273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response.
    Montecucco F; Lenglet S; Carbone F; Boero S; Pelli G; Burger F; Roth A; Bertolotto M; Nencioni A; Cea M; Dallegri F; Fraga-Silva RA; Fougère L; Elfakir C; Gassner AL; Rudaz S; Parissaux X; Wils D; Salomé M; Vuilleumier N; Poggi A; Mach F
    Vascul Pharmacol; 2015 Sep; 72():197-208. PubMed ID: 25921922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The benzoate plant metabolite ethyl gallate prevents cellular- and vascular-lipid accumulation in experimental models of atherosclerosis.
    Liu W; Liu J; Xing S; Pan X; Wei S; Zhou M; Li Z; Wang L; Bielicki JK
    Biochem Biophys Res Commun; 2021 Jun; 556():65-71. PubMed ID: 33839416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amelioration of ulcerative colitis
    Sun T; Kwong CHT; Gao C; Wei J; Yue L; Zhang J; Ye RD; Wang R
    Theranostics; 2020; 10(22):10106-10119. PubMed ID: 32929337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactive oxygen species scavenging and inflammation mitigation enabled by biomimetic prussian blue analogues boycott atherosclerosis.
    Zhang Y; Yin Y; Zhang W; Li H; Wang T; Yin H; Sun L; Su C; Zhang K; Xu H
    J Nanobiotechnology; 2021 May; 19(1):161. PubMed ID: 34059078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating Lipoprotein Transcellular Transport and Atherosclerotic Plaque Formation in ApoE
    Di Francesco V; Gurgone D; Palomba R; Ferreira MFMM; Catelani T; Cervadoro A; Maffia P; Decuzzi P
    ACS Appl Mater Interfaces; 2020 Aug; 12(34):37943-37956. PubMed ID: 32805983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver Fibrosis Amelioration by Macrophage-Biomimetic Polydopamine Nanoparticles via Synergistically Alleviating Inflammation and Scavenging ROS.
    Ma Z; Tian X; Yu S; Shu W; Zhang C; Zhang L; Wang F
    Mol Pharm; 2024 Jun; 21(6):3040-3052. PubMed ID: 38767388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.
    Zhang XQ; Even-Or O; Xu X; van Rosmalen M; Lim L; Gadde S; Farokhzad OC; Fisher EA
    Adv Healthc Mater; 2015 Jan; 4(2):228-36. PubMed ID: 25156796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.